Did Pfizer Pay $43 Billion for a Promise It Couldn't Keep?

When Pfizer completed its $43 billion acquisition of Seagen in December 2023, the strategic logic appeared compelling. Pfizer needed new sources of growth as COVID-19 revenues slowed and established medicines approached greater competitive pressure.

Seagen offered something Pfizer wanted more of: expertise in antibody-drug conjugates (ADCs), a class of cancer medicines designed to deliver toxic payloads to tumour cells¹.

Three years later, the question is not whether Seagen was an attractive company. It is whether Pfizer paid the correct price for what it bought, and crucially, whether the pipeline can deliver the growth needed to justify that price.

The Price of the Future

Pfizer's acquisition thesis extended beyond Seagen's existing medicines. The company presented the transaction as a way to strengthen its oncology franchise, expand its ADC capabilities and accelerate the development of new cancer treatments. Pfizer also projected that Seagen could contribute more than $10 billion in risk-adjusted revenue in 2030¹.

The forecast matters because it reveals the nature of the deal. Pfizer was paying for a combination of current revenues, scientific expertise and future products that had not yet proven they could reach patients at scale.

This is the predicament with pharmaceutical acquisitions. A conventional business may be valued partly on its existing revenues, customers and margins. A promising medicine can become a blockbuster, produce disappointing results, or fail altogether. The value of the pipeline depends on probabilities that can change dramatically after a single clinical trial.

The $43 billion price therefore needs to be judged against more than Seagen's historic sales. It must be assessed against the cash flows Pfizer can realistically generate from the acquired portfolio, after accounting for development costs, commercial investment and the risks of clinical failure.

The First Major Test Has Disappointed

In June 2026, Pfizer reported that sigvotatug vedotin, an experimental ADC acquired through the Seagen transaction, had failed to significantly improve overall survival compared with docetaxel chemotherapy in a Phase 3 trial involving patients with previously treated advanced non-small-cell lung cancer².

The result was significant because the drug was among the first major tests of whether Seagen's research capabilities could generate another valuable medicine under Pfizer's ownership.

There is an important distinction between a disappointing trial and a failed acquisition. Pfizer reported more encouraging trends among patients who had received only one previous line of treatment and continued to pursue the drug in a separate Phase 3 trial combining it with Keytruda in first-line lung cancer².

The medicine's prospects are therefore not necessarily tied to this one result.

Nevertheless, the result demonstrates the risk embedded in Pfizer's original purchase price. A programme that once represented potential future revenue must now be valued in light of a failed primary endpoint, a narrower potential treatment opportunity and further development costs.

And this is not an isolated example of pipeline rationalisation. Pfizer has also discontinued other experimental programmes associated with its oncology research portfolio, including the Seagen-developed ADC SGN-MesoC2³. In September 2026, it licensed another experimental ADC, PF-08046031, to Medicus Pharma after deciding not to continue developing it internally⁴.

That agreement included $12 million upfront, a further $15 million payment scheduled for September 2027, and potential milestone payments and royalties if the programme succeeds⁴.

The deal should not be misread as evidence that the medicine has no value. An external developer may be willing to pursue an asset that no longer fits Pfizer's internal priorities. But it raises a legitimate capital-allocation question: how much of the pipeline Pfizer acquired will ultimately create value inside Pfizer, and how much will be abandoned, partnered or monetised elsewhere?

The Overlooked Defence Of The Deal

In pharmaceutical M&A, the most expensive mistake is paying a premium for a future that clinical trials may never deliver.

The bearish argument has a weakness. It risks treating Seagen as though its value depended entirely on experimental drugs.

The acquisition also brought four marketed cancer medicines into Pfizer's portfolio: Adcetris, used to treat certain lymphomas; Padcev, for bladder and other urothelial cancers; Tivdak, for recurrent or metastatic cervical cancer; and Tukysa, for HER2-positive breast cancer¹.

Together, these four medicines generated approximately $3.46 billion in revenue in 2025⁵. They already provide Pfizer with a substantial source of oncology revenue and, if sales remain strong, should continue to do so regardless of whether experimental drugs such as sigvotatug vedotin succeed.

Final Thoughts

Pfizer may have bought a strong oncology business, but that does not make it a good $43 billion deal. With pipeline setbacks undermining the story that justified the price, Seagen risks becoming a case study in how paying blockbuster prices for scientific potential does not always translate into blockbuster returns.